Effects of policosanol on primary hypercholesterolemia: A 3-year open-extension follow-up

Current Therapeutic Research - Clinical and Experimental

Volumn 58, Issue 11, 1997, Pages 868-875

  Canetti, M Miguel ^a   Moreira, Marta ^b   Más, Rosa ^b   Illnait, José ^b   Fernández, Lilia ^b   Fernández, Julio C ^b  

^a Pathology Department   (Cuba)

^b NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

Cholesterol lowering drugs; Hypercholesterolemia; Long term follow up; Policosanol

Indexed keywords

CHOLESTEROL; PLACEBO; POLICOSANOL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0031406655     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(97)80053-7     Document Type: Article

References (34)

1. Edlavitch SA. Postmarketing surveillance methodologies. Pharmacoepidemiology. 1988; 22:68-78.
2. Arruzazabala M de L, Carbajal D, Más R, et al. Cholesterol-lowering effects of policosanol in rabbits. Biol Res. 1994;27:205-208.
3. Rodríguez C, Mesa R, Más R, et al. Estudio del efecto sobre lípidos y lipoproteínas séricos y de la tolerancia al tratamiento oral con dosis crecientes de policosanol en monos (Macaca arctoides). Arch Venezol Farmacol Terap. 1992;11:74-79.
4. Alemán CL, Más R, Noa C, et al. Carcinogenicity of policosanol in Sprague Dawley rats: A 24 month study. Teratog Carcinog Mutag. 1994;14:239-249.
5. Alemán C, Más R, Hernández C, et al. A 12 months study of policosanol oral toxicity in Sprague-Dawley rats. Toxicol Lett. 1994;70:77-87.
6. Rendón A, Rodríguez MD, López M, et al. Policosanol: A study of its genotoxicity and teratogenicity in rodents. Toxicol Lett. 1992;(Suppl):248. Abstract.
7. Rodríguez C, Mesa R, Más R, et al. Study of policosanol oral chronic toxicity in male monkeys (Macaca arctoides). Food Chem Toxicol. 1993;32:565-575.
8. Rodríguez MD, García H. Teratogenic and reproductive studies of policosanol in the rat and rabbit. Teratog Carcinog Mutag. 1994;14:107-113.
9. Mesa AR, Más R, Noa M, et al. Toxicity of policosanol in beagle dogs: One year study. Toxicol Lett. 1994;73:81-90.
10. Hernández F, Illnait J, Más R, et al. Effect of ateromixol (policosanol) on serum lipids and lipoproteins in healthy volunteers. Curr Ther Res. 1992;4:568-575.
11. Castaño G, Zardoya R, Illnait J, et al. Efectos del tratamiento con ateromixol (PPG) (5 mg) en pacientes con hiperlipoproteinemia tipo II. PCM. 1991;5:21-28.
12. Pons P, Más R, Illnait J, et al. Efficacy and safety of ateromixol (policosanol) in patients with primary hypercholesterolemia. Curr Ther Res. 1992;52:507-513.
13. Soltero I, Fuenmayor I, y Colmenares J. Estudio comparativo doble ciego de la eficacia y tolerancia del policosanol vs bezafibrato en pacientes con hiperlipidemias tipo II. Arch Venezol de Farmacol y Terap. 1993;12:71-76.
14. Pons P, Más R, Illnait J, et al. Effects of ateromixol (policosanol) in elderly hypercholesterolemic patients. Curr Ther Res. 1993;53:265-269.
15. Aneiros E, Calderón B, Más R, et al. Effects of successive dose increases of policosanol on the lipid profile and tolerability of treatment. Curr Ther Res. 1993;54:304-312.
16. Pons P, Rodríguez M, Robaina C, et al. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolemia and tolerability to treatment. J Clin Pharmacol Res. 1994;14:27-33.
17. Pons P, Rodríguez M, Más R, et al. One year efficacy and safety of policosanol in patients with type II hypercholesterolemia. Curr Ther Res. 1994;55:1084-1092.
18. Aneiros E, Más R, Calderón B, et al. Effect of policosanol in lowering-cholesterol levels in patients with type II hypercholesterolemia. Curr Ther Res. 1995;56:176-182.
19. Castaño G, Más R, Nodarse M, et al. One-year study of the efficacy and safety of policosanol (5 mg twice daily) in the treatment of type II hypercholesterolemia. Curr Ther Res. 1995;56:296-304.
20. Castaño G, Canetti M, Moreira M, et al. Efficacy and tolerability of policosanol in elderly patients with type II hypercholesterolemia: A 12 month study. Curr Ther Res. 1995;56: 819-828.
21. Canetti M, Moreira M, Illnait J, et al. One year study on the effect of policosanol (5 mg twice-a-day) on lipid profile in patients with type II hypercholesterolemia. Adv Ther. 1995;12:245-254.
22. Canetti M, Moreira M, Illnait J, et al. A two year study on the efficacy and tolerability of policosanol in patients with type II hypercholesterolemia. Int J Clin Pharmacol Res. 1995;15:159-165.
23. Torres O, Agramonte AJ, Illnait J, et al. Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care. 1995;18:393-397.
24. Arruzazabala ML, Carbajal D, Más R, et al. Effects of policosanol on platelet aggregation in rats. Thromb Res. 1992;69:321-327.
25. Arruzazabala ML, Carbajal D, Molina V, et al. Effect of policosanol on cerebral ischemia in Mongolian gerbils: Role of prostacyclin and thromboxane A2. Prostaglandins Leukotrienes Essent Fatty Acids. 1993;49:695-697.
26. Arruzazabala ML, Carbajal D, Molina V, et al. Estudio farmacológico de la interacción entre el policosanol y la aspirina en animales de experimentación. Rev Iberoam de Trombosis y Hemostasia. 1992;5:17-20.
27. Arruzazabala ML, Valdés S, Más R, et al. Efecto del policosanol sobre la agregación plaquetaria en voluntarios sanos. Symposium on Drug Affecting Lipid Metabolism; 1995; Houston, Tex.
28. Arruzazabala ML, Valdés S, Más R, et al. Effect of policosanol successive dose increase on platelet aggregation in healthy volunteers. Pharmacol Res. 1996;33:1-5.
29. Valdés S, Arruzazabala ML, Carbajal D, et al. Effect of policosanol on platelet aggregation in healthy volunteers. Int J Clin Pharmacol Res. 1996;16:67-72.
30. Noa M, Más R, de la Rosa MC, Magraner J. Effect of policosanol on lipofundin-induced atherosclerotic lesions in rats. J Pharm Pharmacol. 1995;47:289-291.
31. Noa M, de la Rosa MC, Más R. Effect of policosanol on foam cell formation in carrageenan-induced granulomas in rats. J Pharm Pharmacol. 1996;48:306-309.
32. Bacista J, Stusser R, Penichet M, Uguet E. Doppler-ultrasound pilot study of the effects of long-term policosanol therapy on carotid-vertebral atherosclerosis. Curr Ther Res. 1995;56:906-914.
33. O'Brien PC, Shampo MC. Statistical considerations for performing multiple tests in a single experiment. 5. Comparing two therapies with respect to several endpoints. Mayo Clin Proc. 1988;63:1140-1143.
34. Boccuzzi SJ, Keegan ME, Hirsch LJ, et al. Long-term experience with simvastatin. Drug Invest. 1993;5:135-140.